Skip to main content
SpringerLink
Log in

Maintaining stability of sinus rhythm in atrial fibrillation: Antiarrhythmic drugs versus ablation

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

In managing atrial fibrillation, the main therapeutic strategies include rate control, termination of the arrhythmia, and pr vention of recurrences and thromboembolic events. Rate control with digoxin, β-blockers, verapamil, and diltiazem may be preferred in drug refractory and sedentary patients with markedly dilated left atrium and atrial fibrillation of long duration. Drugs useful in the maintenance of sinus rhythm include quinidine, procainamide, disopyramide, sotalol, amiodarone, dofetilide, flecainide, and propafenone. In patients with structural heart disease, the class III antiarrhythmics are the initial drugs of choice, given their neutral effects on survival in a post-myocardial infarction and congestive heart failure population. Due to high recurrence rates with pharmacologic therapy, nonpharmacologic options of therapy include atrioventricular junction ablation, atrial defibrillators, catheter ablation of pulmonary vein foci, and attempts to perform an atrial Maze procedure using catheters. Hybrid therapy using drugs in combination with nonpharmacologic approaches will be used more frequently in the future for refractory patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kannel WB, Abbot RD, Savage DD, McNamara PM: Epidemiologic features of chronic atrial fibrillation. N Eng J Med 1982, 306:1018–1022.

    Article  CAS  Google Scholar 

  2. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983–988.

    PubMed  CAS  Google Scholar 

  3. Alpert JS, Petersen P, Godtfredsen J: Atrial fibrillation: natural history, complications and management. Ann Rev Med 1988, 39:41–52.

    Article  PubMed  CAS  Google Scholar 

  4. Benjamin EJ, Levy D, Vaziri SM, et al.: Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham study. JAMA 1994, 271:840–844.

    Article  PubMed  CAS  Google Scholar 

  5. Brand FN, Abbott RD, Kannel WB: Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up on the Framingham Study. JAMA 1985, 254:3449–3453.

    Article  PubMed  CAS  Google Scholar 

  6. Kopecky SL, Jersh BJ, McGoon MD, et al.: The natural history of lone atrial fibrillation. A population based study over three decades. N Eng J Med 1987, 317:669–674.

    Article  CAS  Google Scholar 

  7. Zipes DP: Atrial fibrillation: from cell to bedside. J Cardiovasc Electrophysiol 1997, 8:927–938.

    Article  PubMed  CAS  Google Scholar 

  8. Haissaguerre M, Jais P, Shah DC, et al.: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998, 339:659–666. Important article defining the initiation of AF by foci originating in the pulmonary veins and the ability to ablate and cure such patients.

    Article  PubMed  CAS  Google Scholar 

  9. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995, 92:1954–1968. Pivotal data demonstrating that AF begets AF.

    PubMed  CAS  Google Scholar 

  10. Tieleman RG, DeLangen CDH, Can Gelder IC, et al.: Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997, 95:1945–1953.

    PubMed  CAS  Google Scholar 

  11. Yu WC, Chen SA, Lee SH, et al.: Tachycardia-induced change of atrial refractory period in humans. Rate dependency and effects of antiarrhythmic drugs. Circulation 1998, 97:2331–2337.

    PubMed  CAS  Google Scholar 

  12. Daoud EG, Knight BP, Wiess R, et al.: Effect of verapamil and procainamide on atrial fibrillation — induced electrical remodeling in humans. Circulation 1997, 96:1542–1550.

    PubMed  CAS  Google Scholar 

  13. Tieleman RG, Van Gelder IC, Crijns HJGM, et al.: Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation induced electrical remodeling in man? J Am Coll Cardiol 1998, 31:167–173.

    Article  PubMed  CAS  Google Scholar 

  14. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al.: Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997, 96:3710–3720.

    PubMed  CAS  Google Scholar 

  15. Pritchett EL: Management of atrial fibrillation. N Engl J Med 1992, 326:1264–1271.

    Article  PubMed  CAS  Google Scholar 

  16. Sopher SM, Camm AJ: Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 1996, 77:24A-37A.

    Article  PubMed  CAS  Google Scholar 

  17. The Planning and Steering Committees of the AFFIRM Study, for the NHLBI AFFIRM Investigators: Atrial fibrillation follow-up investigation of rhythm management — the AFFIRM study design. Am J Cardiol 1997, 79:1198–1202.

    Article  Google Scholar 

  18. Sopher SM, Camm AJ: New trials in atrial fibrillation. J Cardiovasc Electrophysiol 1998, 9:S211-S215.

    PubMed  CAS  Google Scholar 

  19. Hohnloser SH, Kuck KH, Lilienthal J, for the PIAF Investigators: Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet 2000, 356:1789. Pilot data demonstrating that rate control and maintenance of sinus rhythm are comparable.

    Article  PubMed  CAS  Google Scholar 

  20. Klein HO, Kaplinsky E: Digitalis and verapamil in atrial fibrillation and flutter: is verapamil now the preferred agent? Drugs 1986, 31:185–197.

    PubMed  CAS  Google Scholar 

  21. David D, Segni ED, Klein HO, Kaplisky E: Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta-adrenergic blocking agent. Am J Cardiol 1979, 44:1378–1382.

    Article  PubMed  CAS  Google Scholar 

  22. Farshi R, Kistner D, Sarma JSM, et al.: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study if five drug regimens. J Am Coll Cardiol 1999, 33:304–310.

    Article  PubMed  CAS  Google Scholar 

  23. Coplen SE, Antman EM, Berlin JA, et al.: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990, 82:1106–1116.

    PubMed  CAS  Google Scholar 

  24. Karlson BW, Torstensson I, Abjorn C, et al.: Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation: a placebo-controlled one-year follow-up study. Eur Heart J 1988, 9:284–290.

    PubMed  CAS  Google Scholar 

  25. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990, 82:1932–1939.

    PubMed  CAS  Google Scholar 

  26. Naccarelli GV, Dorian P, Hohnsloser SH, Coumel P, for the Flecainide Multicenter Atrial Fibrillation Study Group: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 1996, 77:53A-59A.

    Article  PubMed  CAS  Google Scholar 

  27. Anderson JL, Gilbert EM, Alpert BL, et al.: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, rossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989, 80:1557–1570.

    PubMed  CAS  Google Scholar 

  28. Pritchett ELC, DaTorre SD, Platt ML, et al.: Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. J Am Coll Cardiol 1991, 17:297–303.

    Article  PubMed  CAS  Google Scholar 

  29. Antman EM, Beamer AD, Cantillon C, et al.: Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1989, 12:1005–1011.

    Article  Google Scholar 

  30. Connolly SJ, Hoffert DL: Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989, 63:817–819.

    Article  PubMed  CAS  Google Scholar 

  31. Pritchett ELC, McCarthy EA, Wilkinson WE: Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991, 114:539–544.

    PubMed  CAS  Google Scholar 

  32. Reimold SC, Cantillon CO, Friedman PL, Antman EM: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993, 71:558–563.

    Article  PubMed  CAS  Google Scholar 

  33. Singh S, Zoble RG, Yellen L, et al.: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000, 102:2385–2390.

    PubMed  CAS  Google Scholar 

  34. Connolly SJ, Schnell DJ, Page RL, et al.: Dose-response relations of Azimilide in the management of symptomatic, recurrent atrial fibrillation. Am J Cardiol 2001, 88:974–979.

    Article  PubMed  CAS  Google Scholar 

  35. Horowitz LN, Spielman SR, Greenspan AM, et al.: Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985, 6:1402–1407.

    Article  PubMed  CAS  Google Scholar 

  36. Brodsky MA, Allen BJ, Walker CJ, et al.: Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987, 60:572–574.

    Article  PubMed  CAS  Google Scholar 

  37. Gosselink AT, Crijns HJ, Van Gelder IC, et al.: Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992, 267:3289–3293.

    Article  PubMed  CAS  Google Scholar 

  38. Disch DL, Greenberg ML, Holzberger PT, et al.: Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994, 120:449–457.

    PubMed  CAS  Google Scholar 

  39. Van Gelder IC, Crijns HJGM, Tieleman RG, et al.: Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996, 156:2585–2592.

    Article  PubMed  Google Scholar 

  40. Levy S, Lauribe P, Dolla E, et al.: A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992, 86:1415–1420.

    PubMed  CAS  Google Scholar 

  41. Zehender M, Hohnloser S, Muller B, et al.: Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992, 19:1054–1059.

    Article  PubMed  CAS  Google Scholar 

  42. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al.: Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998, 81:995–998.

    Article  PubMed  CAS  Google Scholar 

  43. Roy D, Talajic M, Thibault B, et al., the CTAF Investigators: Pilot study and protocol of the Canadian Trial of atrial fibrillation (CTAF). Am J Cardiol 1997, 80:464–468. Study showing the superiority of amiodarone over sotalol and propafenone in maintaining sinus rhythm in patients with AF.

    Article  PubMed  CAS  Google Scholar 

  44. Vorperian CR, Havighhurst TC, Miller S, January CT: Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997, 30:791–798.

    Article  PubMed  CAS  Google Scholar 

  45. Page RL, Wilkinson WE, Clair WK, et al.: Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation ad paroxysmal supraventricular tachycardia. Circulation 1994, 89:224–227.

    PubMed  CAS  Google Scholar 

  46. Flaker GC, Blackshear JL, McBride R, et al.: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992, 20:527–532.

    Article  PubMed  CAS  Google Scholar 

  47. Doval HC, Nul DR, Grancelli HO, et al., for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA): Randomized trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994, 344:493–498.

    Article  PubMed  CAS  Google Scholar 

  48. Singh SN, Fletcher RD, Fisher SG, et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995, 333:77–82.

    Article  PubMed  CAS  Google Scholar 

  49. Torp-Pedersen C, Moller M, Bloch-Thomsen PF, et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999, 341:857–865.

    Article  PubMed  CAS  Google Scholar 

  50. Naccarelli GV, Wolbrette DL, Dell’Orfano JT, et al.: A decade of clinical trial developments in post-myocardial infarction, congestive heart failure and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. J Cardiovasc Electrophysiol 1998, 9:864–889.

    Article  PubMed  CAS  Google Scholar 

  51. Camm AJ, Karam R, Pratt C: The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 1998, 81:35D-39D.

    Article  PubMed  CAS  Google Scholar 

  52. Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991, 324:781–788.

    Article  PubMed  CAS  Google Scholar 

  53. Pritchett ELC, Wilkinson WE: Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991, 67:976–980.

    Article  PubMed  CAS  Google Scholar 

  54. Julian DG, Camm AJ, Frangin G, et al., for the European Myocardial Infarct Amiodarone Trial Investigators: Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997, 349:667–674.

    Article  PubMed  CAS  Google Scholar 

  55. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997, 349:675–682.

    Article  PubMed  CAS  Google Scholar 

  56. Julian DG, Prescott RJ, Jackson FS, Szekely P: Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982, 1:1142–1147.

    Article  PubMed  CAS  Google Scholar 

  57. Crijns HJ, van Gelder IC, Lie KI: Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 1988, 62:1303–1306.

    Article  PubMed  CAS  Google Scholar 

  58. Feld GK, Chen P-S, Nicod P, et al.: Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990, 66:378–383.

    Article  PubMed  CAS  Google Scholar 

  59. Selzer A, Wray HW: Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatent of chronic atrial arrhythmias. Circulation 1964, 30:17–26.

    PubMed  CAS  Google Scholar 

  60. Roden DM, Woosley RL, Primm RK: Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986, 111:1088–1093.

    Article  PubMed  CAS  Google Scholar 

  61. Jackman WM, Friday KJ, Anderson JL, et al.: The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovas Dis 1988, 31:115–172.

    Article  CAS  Google Scholar 

  62. Chung MK, Schweikert RA, Wilkoff BL, et al.: hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998, 32:169–176.

    Article  PubMed  CAS  Google Scholar 

  63. Maisel WH, Kuntz KM, Reimold SC, et al.: Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a University Hospital. Ann Intern Med 1997, 127:281–284.

    PubMed  CAS  Google Scholar 

  64. Simons GR, Eisenstein El, Shaw LJ, et al.: Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. Am J Cardiol 1997, 80:1551–1557.

    Article  PubMed  CAS  Google Scholar 

  65. Rinkenberger RL, Naccarelli GV, Berns E, et al.: Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia. Am J Cardiol 1988, 62:44D-55D.

    Article  PubMed  CAS  Google Scholar 

  66. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association/ Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. Circulation 2001, 104:2118–2150. Up-to-date consensus of current management of AF.

    PubMed  CAS  Google Scholar 

  67. Jackman WM, Wang X, Friday KJ, et al.: Catheter ablation of accessory atrioventicular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991, 324:1612–1618.

    Article  Google Scholar 

  68. Langberg JJ, Chin MC, Rosenqvist M, et al.: Catheter ablation of the atrioventricular junction with radiofrequency energy. Circulation 1989, 80:1527–1535.

    PubMed  CAS  Google Scholar 

  69. Jackman WM, Wang X, Friday KJ, et al.: Catheter ablation of the atrioventricular junction using radiofrequency current in seventeen patients: comparison of standard and large-tip catheter electrodes. Circulation 1991, 83:1562–1576.

    PubMed  CAS  Google Scholar 

  70. Kay GN, Ellenbogen KA, Giudici M, et al., and the APT Investigators: The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Interventional Cardiac Electrophysiol 1998, 2:121–135.

    Article  CAS  Google Scholar 

  71. Brignole M, Menozzi C, Gianfranchi L, et al.: Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacologic treatment in patients with heart failure and chronic atrial fibrillation. Circulation 1998, 98:953–960.

    PubMed  CAS  Google Scholar 

  72. Gallagher MM, Obel OA, Camm AJ: Tachycardia-induced atrial myopathy: an important mechanism in the pathophysiology of atrial fibrillation? J Cardiovasc Electrophysiol 1997, 8:1065–1074.

    Article  PubMed  CAS  Google Scholar 

  73. Kieny JR, Sacrez A, Facello A, et al.: Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992, 13:1290–1295.

    PubMed  CAS  Google Scholar 

  74. Packer DL, Brady GH, Worley SJ, et al.: Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986, 57:563–570.

    Article  PubMed  CAS  Google Scholar 

  75. Grogan M, Smith HC, Gersh BJ, Wood DL: Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992, 69:1570–1573.

    Article  PubMed  CAS  Google Scholar 

  76. Rodriguez LM, Smeets JLRM, Xie B, et al.: Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993, 72:1137–1141.

    Article  PubMed  CAS  Google Scholar 

  77. Williamson BD, Man KC, Daoud E, et al.: Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994, 331:910–917.

    Article  PubMed  CAS  Google Scholar 

  78. Feld GK, Fleck RP, Fujimura O, et al.: Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 1994, 90:2299–2307.

    PubMed  CAS  Google Scholar 

  79. Lee SH, Chen SA, Tai CT, et al.: Comparison of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation. J Am Coll Cardiol 1998, 31:637–644.

    Article  PubMed  CAS  Google Scholar 

  80. Saksena S, Prakash A, Hill M, et al.: Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol 1996, 28:687–694.

    Article  PubMed  CAS  Google Scholar 

  81. Papageorgiou P, Anselme F, Kirchhof C, et al.: Coronary sinus pacing prevents induction of atrial fibrillation. Circulation 1997, 96:1893–1898.

    PubMed  CAS  Google Scholar 

  82. Feld GK, Fleck RP, Chen PS, et al.: Radiofrequency catheter ablation for the treatment of human type I atrial flutter. Identification of a critical zone in the reentrant circuit by endocardial mapping techniques. Circulation 1992, 86:1233–1340.

    PubMed  CAS  Google Scholar 

  83. Lesh MD, VanHare GF, Epstein LM, et al.: Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms. Circulation 1994, 89:1074–1089.

    PubMed  CAS  Google Scholar 

  84. Powell AC, Garan H, McGovern BA, et al.: Low energy conversion of atrial fibrillation in the sheep. J Am Coll Cardiol 1992, 20:707–711.

    Article  PubMed  CAS  Google Scholar 

  85. Lau CP, Tse HF, Lok NS, et al.: Initial clinical experience with an implantable human atrial defibrillator. PACE 1997, 20:220–225.

    PubMed  CAS  Google Scholar 

  86. Heisel A, Jung J: The atrial defibrillator: a stand-alone device or part of a combined dual-chamber system? Am J Cardiol 1999, 83:218D-226D.

    Article  PubMed  CAS  Google Scholar 

  87. Cox JL, Scheussler RB, Lappas DG: An 8 1/2 year clinical experience with surgery for atrial fibrillation. Ann Surg 1996, 224:267–275.

    Article  PubMed  CAS  Google Scholar 

  88. Haissaguerre M, Jais P, Shah D, et al.: Right and left atrial radiofrequency catheter therapy for paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996, 7:1132–1144.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Hershey Medical Center, 500 University Drive, 17033, Hershey, PA, USA

    Gerald V. Naccarelli MD, John Hynes MD, Deborah L. Wolbrette MD, Luna Bhatta MD, Mazhar Khan MD & Jerry Luck MD

Authors
  1. Gerald V. Naccarelli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Hynes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deborah L. Wolbrette MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luna Bhatta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mazhar Khan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jerry Luck MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naccarelli, G.V., Hynes, J., Wolbrette, D.L. et al. Maintaining stability of sinus rhythm in atrial fibrillation: Antiarrhythmic drugs versus ablation. Curr Cardiol Rep 4, 418–425 (2002). https://doi.org/10.1007/s11886-002-0042-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-002-0042-4

Keywords

Search

Navigation